PARP1 and kidney disorder: For example, INO1001, a highly potent PARP1 inhibitor, could prevent oxidative stress and improve nephropathy in diabetic mice (Szabo et al., 2006) and relieve aging-associated cardiac and vascular dysfunction (Radovits et al., 2007).